Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis

Language
en
Document Type
Article
Issue Date
2023-02-06
First published
2023-01-19
Issue Year
2023
Authors
Schulmeyer, Carla E.
Fasching, Peter A.
Häberle, Lothar
Meyer, Julia
Schneider, Michael
Wachter, David
Ruebner, Matthias
Pöschke, Patrik
Beckmann, Matthias W.
Hartmann, Arndt
Editor
Publisher
MDPI
Abstract

Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort–case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.

Journal Title
Diagnostics
Volume
13
Issue
3
Citation
Diagnostics 13.3 (2023): 372. <https://www.mdpi.com/2075-4418/13/3/372>
Zugehörige ORCIDs